BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Innovent Biologics, Incyte ink licensing deal for potential $391.5M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Innovent Biologics, Incyte ink licensing deal for potential $391.5M
Dec. 19, 2018
By
Elise Mak
No Comments
HONG KONG – In a deal involving up to $391.5 million, HKEX-listed Innovent Biologics Inc. (HKG:1801) in-licensed three clinical-stage assets from Incyte Corp. to develop and commercialize them in the Chinese mainland, Hong Kong, Macau and Taiwan.
BioWorld